BACKGROUND Radioactive iodine as a treatment modality has been shown in several studies to be a safe and effective therapy for Graves disease. However, there is still no uniformity regarding optimal dosing method. The aim of this study is to compare the efficacy of calculated and fixed dosing of radioiodine for the treatment of Graves disease. METHODS A hundred twenty-two patients diagnosed w...

Controversy remains regarding the optimal dose calculation with radioiodine therapy for patients with Graves' disease. Here, we focused our analysis on data concerning the patient's pretreatment background, an empirically set dose of radioiodine and the post-treatment thyroid function, and investigated those factors that affected the outcome. The subjects consisted of 38 patients diagnosed as h...

OBJECTIVES To evaluate abortion and fetal congenital anomaly rates in women previously submitted to radioiodine therapy for differentiated thyroid carcinoma. STUDY DESIGN A case-control study of 108 pregnant women, 48 cases whose pregnancies were evaluated after they had undergone radioiodine therapy for differentiated thyroid carcinoma, and the control group consisted of 60 healthy pregnant ...

undesired radiation exposure to caregivers is an important problem in radioiodine therapy in thyroid carcinoma patients, especially when patient is non-ambulatory. special precautions are needed to keep the exposure to caregivers low when higher dose of radioiodine is necessary. here we present a case-report of a 74-year old male patient with papillary thyroid carcinoma with local invasion and ...

Salivary gland involvement is one of the radioiodine therapy complications. Salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. Methods: Salivary gland scintigraphy was performed with Tc-99m Pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. Ejection Fraction (EF) of parotid and submandibula...

The aim of this study was to review the outcome of ablative radioiodine treatment on ovarian function in young women treated for differentiated thyroid carcinoma. Of 1398 patients with differentiated thyroid cancer, 496 were women under the age of 40 at the time of diagnosis who had received radioiodine therapy. Of these, 322 received a single 3 GBq ablation dose of radioiodine while the remain...

INTRODUCTION Autoimmunity against the TSH receptor is a key pathogenic element in Graves' disease. The autoimmune aberration may be modified by therapy of the hyperthyroidism. OBJECTIVE To compare the effects of the common types of therapy for Graves' hyperthyroidism on TSH-receptor autoimmunity. METHODS Patients with newly diagnosed Graves' hyperthyroidism aged 20-55 years were randomized ...

BACKGROUND AND OBJECTIVE Patient satisfaction is of paramount importance when delivering a patient-centered service. Our hospital has been a center for the use of radioiodine to treat thyrotoxicosis for several years, but we began carrying out patient satisfaction surveys and implementing changes after 2008. The aim of the project reported here was to assess patient satisfaction with our radioi...

BACKGROUND To detect recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of thyroid hormone therapy may be required to raise serum thyrotropin concentrations to stimulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed. However, withdrawal of thyroid hormone therapy causes hypothyroidism. Administration of recombinant human thy...

BACKGROUND In order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor - TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor - TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1). DESIGN AND...